Mohammad Alashqar Shares Novel Antithrombin-Targeting Therapy for Hemophilia A and B
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
“Grateful to share that my review paper, ‘Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,’ has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback. This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.
Title: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Read the article.”
Deepen your hematology knowledge with Hemostasis Today.
-
Apr 14, 2026, 15:43Webinar on Aplastic Anemia Clinical Case – ASH
-
Apr 14, 2026, 15:42Heghine Khachatryan: Endometriosis Is Not Only a Pain Disorder
-
Apr 14, 2026, 15:36Alisha Tuck: Navigating the First Trimester with Ultrasound and Anticoagulation Management
-
Apr 14, 2026, 15:26Tijjani Balas: The End of ‘Type O Negative’ Shortages? – A New Era in Blood Transfusion
-
Apr 14, 2026, 15:07Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
-
Apr 14, 2026, 15:05Matteo Foschi: ASPERA-R Study Reveals Competing Causes Of Breakthrough Stroke On Anticoagulation
-
Apr 14, 2026, 14:48Samwel Mikaye: From Virchow’s Triad to Prevention of PE in Patients with DVT
-
Apr 14, 2026, 14:43Chokri Ben Lamine: Diamond – Blackfan Anemia and Congenital Dyserythropoietic Anemia Pearls
-
Apr 14, 2026, 14:14From the Clinical Transfusion Working Party – 2025 International Platelet Transfusion Guidelines – ISBT